Market Capitalisation is a Better Valuation Metric Than Share Price, page-94

Ha Ha ... my post really seems to have stirred the nest.

To be quite frank, I was getting a little tired of the many people posting that they would jump at $50 if it was on the table tomorrow.

My post was really to demonstrate one practical model that would result in a share price above $50.
As you can see in my model the end game was for a Big Pharma to take out both NEU and Acadia in a step phase process, with at each stage a 1.5 times moderate uplift. Quite a reasonable model without getting too carried away.

My goals are very simple and have always been that way when I invest in biotech companies more than any other industry:

• I really like investing in companies where the outcomes provide goodness to people - those suffering, their families and care givers
• The biotech companies have a strong Board, Senior Mgt Team, Researchers & Advisory Team that "do what they say they will do"
• The companies stay true to its goals and continues to deliver whilst dealing with the challenges along the way in their stride
• A company that respects it target audience (patients) and the wide variety of shareholders - maximises $$$$ spent on its programs
• Delivers the outcomes with modesty and pride.

For me, my investment in NEU in reflected in these statements.

I really don't mind who takes control of NEU as long as they show a similar dedication to the cause of improving the lives of those suffering.

Wonderful year in 2023 and I am confident the good news will continue into an exciting 2024 and beyond.

Happy New Year

GLTA